A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated ...
Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...
They say that a picture is worth a thousand words. But images are also dense with data and that is why ophthalmology is the vanguard of specialties using artificial intelligence (AI), explains Alfredo ...
Overall, the median duration of b/tsDMARD use was 4.3 years, longer in RA (6.3 years) than axSpA (3 years). TNF inhibitors were the most commonly used treatment (80.7%), with axSpA patients more often ...
Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...
A real-world analysis has confirmed the negative impact on patients when they lose copay assistance for treatments for retina and macular disease. Presented today during a session at the annual ...
If the future of retina specialty is to be bright, providers must care for their bodies, advocate for their businesses and create a more inclusive culture, according to this morning’s session at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback